Business Description
Molecular Partners AG
SIC : 2836
ISIN : CH0256379097
Total Employee Number:
134Compare
Compare
Traded in other countries / regions
MOLN.SwitzerlandMLLCF.USA6ML.Germany0QXX.UK IPO Date
2014-10-23Description
Molecular Partners AG is a clinical-stage Swiss biopharmaceutical company based in Zurich that develops a proprietary class of engineered proteins known as DARPin therapeutics, designed as alternatives to antibodies for treating serious diseases. Its pipeline spans oncology, immuno-oncology, and ophthalmology, with candidates developed both independently and through partnerships with larger pharmaceutical companies. The company's lead programs include radio-DARPin candidates that deliver therapeutic radiation to tumors, as well as earlier-stage compounds targeting cancer and sight-threatening eye disorders. Molecular Partners generates revenue primarily through collaboration and licensing agreements, including research funding, milestone payments, and royalties, alongside income from partnered development activities. Its partners have included Novartis and Amgen, among others. The company operates mainly in Switzerland and conducts clinical trials internationally, with a focus on the United States and European markets. As a clinical-stage firm, it has no approved products and depends on partnerships and capital markets to fund development.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 22.33 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.78 | |||||
9-Day RSI | 35.66 | |||||
14-Day RSI | 41.33 | |||||
3-1 Month Momentum % | 11.1 | |||||
6-1 Month Momentum % | -5.92 | |||||
12-1 Month Momentum % | 22.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.27 | |||||
Quick Ratio | 7.27 | |||||
Cash Ratio | 6.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | -0.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -62.5 | |||||
ROA % | -51 | |||||
ROIC % | -950.04 | |||||
3-Year ROIIC % | 1983.27 | |||||
ROC (Joel Greenblatt) % | -1213.28 | |||||
ROCE % | -57.16 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 14.17 | |||||
PB Ratio | 2.12 | |||||
Price-to-Tangible-Book | 2.12 | |||||
EV-to-EBIT | -1.32 | |||||
EV-to-Forward-EBIT | 7.13 | |||||
EV-to-EBITDA | -1.37 | |||||
EV-to-Forward-EBITDA | 6.9 | |||||
EV-to-Forward-Revenue | 14.36 | |||||
EV-to-FCF | -1.35 | |||||
Price-to-GF-Value | 9.06 | |||||
| Price-to-Net-Current-Asset-Value | 2.28 | |||||
| Price-to-Net-Cash | 2.43 | |||||
Earnings Yield (Greenblatt) % | -75.93 | |||||
FCF Yield % | -34.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | |||
| EPS (TTM) (CHF) | -1.359 | ||
| Beta | 0.5364 | ||
| 3-Year Sharpe Ratio | 0.05 | ||
| 3-Year Sortino Ratio | 0.12 | ||
| Volatility % | 36.78 | ||
| 14-Day RSI | 41.33 | ||
| 14-Day ATR (CHF) | 0.045394 | ||
| 20-Day SMA (CHF) | 3.424 | ||
| 12-1 Month Momentum % | 22.53 | ||
| 52-Week Range (CHF) | 2.72 - 3.94 | ||
| Shares Outstanding (Mil) | 38.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Partners AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Partners AG Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-12 16:00 | In 172 days | ||
| Annual report for 2026 | 2027-03-12 | In 171 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-12 | In 171 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-25 | 3.53 (+1.44%) | ||
| Second quarter earnings results for 2026 | 2026-08-25 | 3.53 (+1.44%) | ||
| TD Cowen\'s 7th Annual Oncology Innovation Summit | 2026-05-27 11:30 | 3.08 (-2.84%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.18 (+0.00%) | ||
| General meeting for 2026 | 2026-04-14 09:00 | 3.17 (-7.58%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-12 16:00 | 3.75 (+1.76%) | ||
| Annual report for 2025 | 2026-03-12 | 3.75 (+1.76%) |
Show
Entries
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(LTS:0QXX)'s stock price today?
The current price of LTS:0QXX is CHF3.40. The 52 week high of LTS:0QXX is CHF3.94 and 52 week low is CHF2.72.
When is next earnings date of Molecular Partners AG(LTS:0QXX)?
The next earnings date of Molecular Partners AG(LTS:0QXX) is 2026-11-25 Est..
Does Molecular Partners AG(LTS:0QXX) pay dividends? If so, how much?
Molecular Partners AG(LTS:0QXX) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers